What is NDC 71335-2221?

71335-2221 is the product NDC for Methotrexate, Methotrexate sodium 2.5 mg/1 tablet, listed with the FDA by Bryant Ranch Prepack. It has 8 package NDCs, shown above in 10- and 11-digit form.

Bryant Ranch Prepack, NDC labeler code 71335. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.

What other NDCs exist for Methotrexate?

51 other product NDCs are listed under this name.

Is there a related HCPCS / J-code?

Not in Med-Code's curated HCPCS directory.

Methotrexate NDC 71335-2221 | National Drug Code

NDC codes

FDA NDC Directory

Product NDC (as listed)71335-2221Labeler and product segments. Claims need a package NDC.

Product NDC at billing width71335-2221Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package
71335-2221-1	7133522210171335222101	30 TABLET in 1 BOTTLE (71335-2221-1)Marketed from Aug 15, 2023
71335-2221-2	7133522210271335222102	12 TABLET in 1 BOTTLE (71335-2221-2)Marketed from Aug 15, 2023
71335-2221-3	7133522210371335222103	20 TABLET in 1 BOTTLE (71335-2221-3)Marketed from Aug 15, 2023
71335-2221-4	7133522210471335222104	100 TABLET in 1 BOTTLE (71335-2221-4)Marketed from Aug 15, 2023
71335-2221-5	7133522210571335222105	36 TABLET in 1 BOTTLE (71335-2221-5)Marketed from Aug 15, 2023
71335-2221-6	7133522210671335222106	24 TABLET in 1 BOTTLE (71335-2221-6)Marketed from Aug 15, 2023
71335-2221-7	7133522210771335222107	90 TABLET in 1 BOTTLE (71335-2221-7)Marketed from Aug 15, 2023
71335-2221-8	7133522210871335222108	4 TABLET in 1 BOTTLE (71335-2221-8)Marketed from Aug 15, 2023

How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Methotrexate
Generic name (nonproprietary): methotrexate
Active ingredients: Methotrexate sodium — 2.5 mg/1
Dosage form: Tablet
Route: Oral
Labeler: Bryant Ranch PrepackNDC labeler code 71335
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 210454
Marketing start: Jan 30, 2020
Listing expires: Dec 31, 2027
Other FDA classes: Folic Acid Metabolism Inhibitors (Mechanism)
Identifiers: Product ID 71335-2221_5c146783-d4cc-4700-87b9-1fd872af6913SPL ID 5c146783-d4cc-4700-87b9-1fd872af6913SPL set ID b6e61c50-024a-494f-b04c-100fb371a837RxCUI 105585UNII 3IG1E710ZN
Pharmacologic class: Folate Analog Metabolic Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N471335222101 followed by a unit qualifier and the quantity

Package 71335-2221-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jun 10, 2026. This label includes a boxed warning.

Indications (excerpt from the label)

Methotrexate tablets are a dihydrofolate reductase inhibitor indicated for the: Treatment of adults and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen ( 1.1 ) Treatment of adults with mycosis fungoides ( 1.1 ) Treatment of adults with relapsed or refractory non-Hodgkin lymphoma as part of a metronomic combination regimen ( 1.1 ) Treatment of adults with rheumatoid arthritis ( 1.2 ) Treatment of pediatric patients with polyarticular juvenile idiopathic arthritis (pJIA) ( 1.3 ) Treatment of adults with severe psoriasis ( 1.4 ) 1.1 Neoplastic Diseases Methotrexate tablets are indicated for the: treatment of adults and pediatr…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

About NDC 71335-2221

What is NDC 71335-2221?: 71335-2221 is the product NDC for Methotrexate, Methotrexate sodium 2.5 mg/1 tablet, listed with the FDA by Bryant Ranch Prepack. It has 8 package NDCs, shown above in 10- and 11-digit form.
What drug is associated with this NDC?: Methotrexate.
What is the active ingredient?: Methotrexate sodium.
Who is the labeler?: Bryant Ranch Prepack, NDC labeler code 71335. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for Methotrexate?: 51 other product NDCs are listed under this name. See all Methotrexate NDCs.
Is there a related HCPCS / J-code?: Not in Med-Code's curated HCPCS directory. See Billing references above.

Other finished products listed under the same name: strengths, forms and labelers.

Other Methotrexate NDCs
Product	Strength	Form · route	Labeler	Product NDC	Package NDCs (11-digit)
Methotrexate	Methotrexate 2.5 mg/1	TabletOral	American Health Packaging	60687-975	60687-0975-94
Methotrexate	Methotrexate sodium 25 mg/mL	Injection, SolutionIntramuscular, Intravenous, Subcutaneous	Alembic Pharmaceuticals Limited	46708-711	46708-0711-05
Methotrexate	Methotrexate sodium 25 mg/mL	Injection, SolutionIntramuscular, Intrathecal, Intravenous, Subcutaneous	Alembic Pharmaceuticals Limited	46708-712	46708-0712-01
Methotrexate	Methotrexate sodium 25 mg/mL	Injection, SolutionIntramuscular, Intravenous, Subcutaneous	Alembic Pharmaceuticals Inc.	62332-711	62332-0711-05
Methotrexate	Methotrexate sodium 25 mg/mL	Injection, SolutionIntramuscular, Intrathecal, Intravenous, Subcutaneous	Alembic Pharmaceuticals Inc.	62332-712	62332-0712-01
Methotrexate	Methotrexate 2.5 mg/1	TabletOral	AvPAK	50268-554	50268-0554-15
Methotrexate	Methotrexate sodium 2.5 mg/1	TabletOral	Safecor Health LLC	48433-065	48433-0065-05
Methotrexate	Methotrexate sodium 2.5 mg/1	TabletOral	Coupler LLC	67046-1524	67046-1524-03
Methotrexate	Methotrexate sodium 25 mg/mL	Injection, SolutionIntramuscular, Intrathecal, Intravenous, Subcutaneous	Hospira, Inc.	61703-161	61703-0161-05
Methotrexate	Methotrexate sodium 50 mg/2mL	Injection, SolutionIntramuscular, Intrathecal, Intravenous, Subcutaneous	Eugia US LLC	55150-510	55150-0510-0155150-0510-05

All 52 Methotrexate NDCs

Other NDCs under ANDA 210454

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 210454
Product	Strength	Form · route	Labeler	Product NDC
Methotrexate	Methotrexate sodium 2.5 mg/1	TabletOral	Aurobindo Pharma Limited	59651-182
Methotrexate	Methotrexate sodium 2.5 mg/1	TabletOral	Chartwell RX, LLC	62135-772
Methotrexate	Methotrexate sodium 2.5 mg/1	TabletOral	NuCare Pharmaceuticals, Inc.	68071-3765